Cumulative Tenofovir Diphosphate Exposure in Persons with HIV Taking Single- Vs. Multiple-tablet Regimens

Methods: Blood for DBS was prospectively collected in PWH on TDF during 1144 person visits (n = 523). Linear mixed-effects models, adjusted for baseline characteristics, were used to compare TFV-DP in STR versus MTR. Models adjusted for ART regimen using either anchor drug class, pharmacokinetic booster status (unboosted [u/] or boosted [b/]), or a combined STR/MTR and booster categorical variable.

Results: In the anchor class-adjusted model, STR had 19% (95% confidence interval [CI]: 3%-37%; p = 0.02) higher TFV-DP concentrations than MTR. However, in the booster-adjusted model, STR was not significantly higher than MTR (estimate 5%, 95% CI: -9% to 21%; p = 0.48), although PWH on b/ART had 35% (95% CI: 16%-58%; p = 0.0001) higher TFV-DP than u/ART. In the STR/MTR-boosted variable model, when compared to u/MTR, b/STR, b/MTR, and u/STR had 25% (95% CI: 7%-47%; p = 0.005), 37% (95% CI: 17%-59%; p < 0.0001), and 7% (95% CI: -7% to 24%; p = 0.34) higher TFV-DP, respectively. Compared with b/MTR, b/STR had 9% (95% CI: -31% to 10%; p = 0.37) lower TFV-DP. In a sensitivity analysis of PWH with HIV viral load <20 copies/ml at all visits, b/STR and b/MTR had 34% (95% CI: 16%-55%; p < 0.0001) and 12% (95% CI: -2% to 27%; p = 0.09) higher TFV-DP, respectively, compared with u/MTR, while u/STR had 4% (95% CI: -15% to 8%; p = 0.50) lower TFV-DP. Compared with b/MTR, b/STR had 17% (95% CI: 2%-30%; p = 0.03) higher TFV-DP.

Conclusions: Persons with HIV on b/TDF-based ART had higher TFV-DP than u/ART, regardless of STR or MTR use. No significant differences in TFV-DP between regimens of the same boosting status (i.e., b/STR vs. b/MTR; u/STR vs. u/MTR) were observed in the full cohort. Future research should examine the clinical utility of these findings in patient-tailored ART selection.

Citing Articles

Demographic and Clinical Characteristics of Persons with HIV with Viral Load:Adherence Mismatch Who Are at Risk of Future Viremia.

Grinsteiner E, Morrow M, MaWhinney S, Coyle R, Coleman S, Zheng J AIDS Res Hum Retroviruses. 2022; 39(1):33-37.

PMID: 36301917 PMC: 9889007. DOI: 10.1089/AID.2021.0218.

References

Yager J, Faragon J, McGuey L, Hoye-Simek A, Hecox Z, Sullivan S . Relationship Between Single Tablet Antiretroviral Regimen and Adherence to Antiretroviral and Non-Antiretroviral Medications Among Veterans' Affairs Patients with Human Immunodeficiency Virus. AIDS Patient Care STDS. 2017; 31(9):370-376. DOI: 10.1089/apc.2017.0081. View

Zheng J, Rower C, McAllister K, Castillo-Mancilla J, Klein B, Meditz A . Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots. J Pharm Biomed Anal. 2016; 122:16-20. PMC: 4764437. DOI: 10.1016/j.jpba.2016.01.038. View

Hemmige V, Flash C, Carter J, Giordano T, Zerai T . Single tablet HIV regimens facilitate virologic suppression and retention in care among treatment naïve patients. AIDS Care. 2018; 30(8):1017-1024. PMC: 6094383. DOI: 10.1080/09540121.2018.1442554. View

Castillo-Mancilla J, Zheng J, Rower J, Meditz A, Gardner E, Predhomme J . Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2012; 29(2):384-90. PMC: 3552442. DOI: 10.1089/AID.2012.0089. View

Mann S, Morrow M, Coyle R, Coleman S, Saderup A, Zheng J . Lower Cumulative Antiretroviral Exposure in People Living With HIV and Diabetes Mellitus. J Acquir Immune Defic Syndr. 2020; 85(4):483-488. PMC: 7756101. DOI: 10.1097/QAI.0000000000002460. View

Kearney B, Mathias A, Mittan A, Sayre J, Ebrahimi R, Cheng A . Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2006; 43(3):278-83. DOI: 10.1097/01.qai.0000243103.03265.2b. View

Castillo-Mancilla J, Edwards J, Brijkumar J, Moosa M, Zhao Y, Ofotokun I . Tenofovir diphosphate levels in dried blood spots are associated with virologic failure and resistance to first-line therapy in South Africa: a case-control cohort study. J Int AIDS Soc. 2021; 24(12):e25849. PMC: 8673924. DOI: 10.1002/jia2.25849. View

Castillo-Mancilla J, Morrow M, Coyle R, Coleman S, Gardner E, Zheng J . Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections. Clin Infect Dis. 2018; 68(8):1335-1342. PMC: 6451996. DOI: 10.1093/cid/ciy708. View

Cotte L, Ferry T, Pugliese P, Valantin M, Allavena C, Cabie A . Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study. PLoS One. 2017; 12(2):e0170661. PMC: 5289500. DOI: 10.1371/journal.pone.0170661. View

10.

Chakraborty A, Qato D, Awadalla S, Hershow R, Dworkin M . Antiretroviral therapy adherence among treatment-naive HIV-infected patients. AIDS. 2019; 34(1):127-137. DOI: 10.1097/QAD.0000000000002384. View

11.

Saderup A, Morrow M, Libby A, Coyle R, Coleman S, Zheng J . Higher medication complexity in persons with HIV is associated with lower tenofovir diphosphate in dried blood spots. Pharmacotherapy. 2021; 41(3):291-298. PMC: 7946741. DOI: 10.1002/phar.2490. View

12.

van Gelder J, Deferme S, Naesens L, De Clercq E, van den Mooter G, Kinget R . Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures. Drug Metab Dispos. 2002; 30(8):924-30. DOI: 10.1124/dmd.30.8.924. View

13.

Castillo-Mancilla J, Haberer J . Adherence Measurements in HIV: New Advancements in Pharmacologic Methods and Real-Time Monitoring. Curr HIV/AIDS Rep. 2018; 15(1):49-59. PMC: 5876155. DOI: 10.1007/s11904-018-0377-0. View

14.

Whiteley L, Olsen E, Haubrick K, Odoom E, Tarantino N, Brown L . A Review of Interventions to Enhance HIV Medication Adherence. Curr HIV/AIDS Rep. 2021; 18(5):443-457. DOI: 10.1007/s11904-021-00568-9. View

15.

Morrow M, MaWhinney S, Coyle R, Coleman S, Gardner E, Zheng J . Predictive Value of Tenofovir Diphosphate in Dried Blood Spots for Future Viremia in Persons Living With HIV. J Infect Dis. 2019; 220(4):635-642. PMC: 6639595. DOI: 10.1093/infdis/jiz144. View

16.

Anderson P, Liu A, Castillo-Mancilla J, Gardner E, Seifert S, McHugh C . Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy. Antimicrob Agents Chemother. 2017; 62(1). PMC: 5740314. DOI: 10.1128/AAC.01710-17. View

17.

Tong L, Phan T, Robinson K, Babusis D, Strab R, Bhoopathy S . Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother. 2007; 51(10):3498-504. PMC: 2043290. DOI: 10.1128/AAC.00671-07. View

18.

Libby A, Fish D, Hosokawa P, Linnebur S, Metz K, Nair K . Patient-level medication regimen complexity across populations with chronic disease. Clin Ther. 2013; 35(4):385-398.e1. DOI: 10.1016/j.clinthera.2013.02.019. View

19.

Metz K, Fish D, Hosokawa P, Hirsch J, Libby A . Patient-Level Medication Regimen Complexity in Patients With HIV. Ann Pharmacother. 2014; 48(9):1129-1137. DOI: 10.1177/1060028014539642. View

20.

Cohen M, Chen Y, McCauley M, Gamble T, Hosseinipour M, Kumarasamy N . Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med. 2016; 375(9):830-9. PMC: 5049503. DOI: 10.1056/NEJMoa1600693. View